Abstract:RNAs with 5′‐triphosphate (ppp) are detected in the cytoplasm principally by the innate immune receptor RIG‐I, whose activation triggers a Type I interferon response. Cellular RNAs undergo post‐transcriptional modifications which ensures that self RNAs do not carry 5′ppp and/or blunt‐ends. We carried out a thorough biochemical characterization of RIG‐I complexes with RNAs carrying various end‐modifications as well as measured the effect of these end‐modifications on their signaling activity. We find that discrimination of RNA ligands occurs at multiple stages and signaling RNAs have high affinity and ATPase turnover rate and thus a high k atpase / K d . Our studies reveal that the autoinhibitory interface between CARD2 (second CARD) and Hel2i (Helicase 2 insertion domain) plays a critical role in RNA selectivity, wherein this interface acts as a “gate” that prevents cellular RNAs from generating productive complexes that can signal. It is thought that self RNAs like mRNAs are not recognized by RIG‐I because 5′ppp is capped by the addition of a 7‐methyl guanosine (m7G) (Cap‐0) and the 5′‐end nucleotide ribose is 2′‐O‐methylated (Cap‐1). We provide a structural and mechanistic basis for the exact roles of capping and 2′‐O‐methylation in evading RIG‐I recognition using enzymatic assays, X‐ray crystallography and cell‐based signaling studies. Surprisingly, we find that Cap‐0 and 5′ppp dsRNA have similar binding affinities, activate RIG‐I's ATPase to the same extent, and shows the same cellular signaling response. Three new crystal structures of RIG‐I complexes with dsRNA bearing 5′OH, 5′ppp, and 5′Cap‐0 reveal that RIG‐I accommodates m7G in a cavity created through conformational changes in helicase‐motif IVa without perturbing the triphosphate interactions. In contrast, Cap‐1 modifications abrogate RIG‐I signaling through a mechanism involving the H830 residue, wherein 2′‐O‐methylation works synergistically with m7G capping to weaken RNA affinity and ATPase activity. Our work provides new structural insights into the host and viral immune evasive mechanisms from RIG‐I explaining the complexity of cap structures over evolution. Support or Funding Information This work was supported by NIH grant GM111959 to Joseph Marcotrigiano and Smita S Patel.

RIG-I Uses an ATPase-Powered Translocation-Throttling Mechanism for Kinetic Proofreading of RNAs and Oligomerization

Kinetic discrimination of self/non-self RNA by the ATPase activity of RIG-I and MDA5

Structural and Mechanistic Basis for Self Versus Non‐self RNA Discrimination by the Innate Immune Receptor RIG‐I

The structural basis of 5' triphosphate double-stranded RNA recognition by RIG-I C-terminal domain.

Structural basis of RNA recognition and activation by innate immune receptor RIG-I

Structural and Functional Insights into 5′-Ppp RNA Pattern Recognition by the Innate Immune Receptor RIG-I

HDX-MS Reveals Dysregulated Checkpoints That Compromise Discrimination Against Self RNA During RIG-I Mediated Autoimmunity.

Reconstitution of the RIG-I Pathway Reveals a Signaling Role of Unanchored Polyubiquitin Chains in Innate Immunity

Structural and biochemical studies of RIG-I antiviral signaling

Structural Basis for M7g Recognition and 2′-O-methyl Discrimination in Capped RNAs by the Innate Immune Receptor RIG-I

The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses

A ribosomal RNA fragment with 2′,3′-cyclic phosphate and GTP-binding activity acts as RIG-I ligand

Agonist and Antagonist Recognition by Rig-I, A Cytoplasmic Innate Immunity Receptor

Crystal Structure Of Rig-I C-Terminal Domain Bound To Blunt-Ended Double-Strand Rna Without 5' Triphosphate

RIG-I recognizes metabolite-capped RNAs as signaling ligands

RIG-I like receptor sensing of host RNAs facilitates the cell-intrinsic immune response to KSHV infection

A Hierarchical Mechanism of RIG-I Ubiquitination Provides Sensitivity, Robustness and Synergy in Antiviral Immune Responses

A Loosened Gating Mechanism of RIG-I Leads to Autoimmune Disorders.

Mechanism of TRIM25 Catalytic Activation in the Antiviral RIG-I Pathway

5'-Triphosphate-dependent Activation of PKR by RNAs with Short Stem-Loops

A conserved isoleucine in the binding pocket of RIG-I controls immune tolerance to mitochondrial RNA